Morgan Stanley maintained Overweight on Dyne Therapeutics, Inc. (DYN) on March 02, 2026. This DYN analyst rating came with a price target lowered to $47, and the firm left the core rating unchanged.

The March 02, 2026 note was logged at 11:12 AM and showed a modest share move of 0.62% ($0.10) at the time of the update. Investors should read the PT cut alongside the maintained Overweight view to understand the firm’s risk and reward recalibration.

DYN analyst rating: Morgan Stanley maintains Overweight on March 02, 2026

Morgan Stanley kept its Overweight rating for Dyne Therapeutics on March 02, 2026. The firm explicitly lowered its price target to $47 while keeping the structural buy view intact.

The single published action lists the timestamp as 11:12 AM and reports a 0.62% ($0.10) price change at the moment StreetInsider captured the note. The update signals confidence in Dyne’s longer-term thesis even as near-term assumptions shifted.

DYN price target update and source

Morgan Stanley lowered the target to $47, the key numeric change in the March 02, 2026 bulletin. The change came with no change to the Overweight rating, indicating a trimmed upside estimate rather than lost conviction.

Full details are available in the reporting by StreetInsider for the Morgan Stanley note source.

What the DYN analyst rating means for investors

Maintaining Overweight means Morgan Stanley still expects Dyne to outperform peers over their forecast horizon. The lowered $47 target narrows the implied upside from current prices and shifts return expectations.

For investors, this is a signal to weigh continued analyst support against lower near-term upside. The rating change itself is supportive, but the PT cut advises caution on expected returns.

Historical analyst coverage and context for DYN

Morgan Stanley is the only firm in this recent update, and the March 02, 2026 note is the latest in periodic coverage of Dyne. Historical coverage typically mixes Overweight and Neutral stances as pipeline and trial results evolve.

Dyne trades with a market cap of $2,659,133,611, placing it in the mid-cap biotech range where analyst views often shift on clinical milestones and cash runway updates.

Impact on DYN stock performance and key metrics

The reported StreetInsider capture recorded a 0.62% ($0.10) price change around the note, showing muted immediate market reaction. Price target edits often change expectations more than intraday flows for mid-cap biotech names.

Investors should monitor volume and follow-up commentary from other firms to see if the Morgan Stanley target move triggers broader re-rating.

What to watch next for DYN: catalysts, risks and timeline

Key near-term catalysts include upcoming clinical readouts, regulatory steps, and partnership or financing news. Any positive trial news could widen the gap between current price and the $47 target.

Risks include slower-than-expected trial progress, higher cash burn, and sector volatility. We recommend tracking subsequent analyst notes and company releases closely to see if the DYN analyst rating evolves.

Final Thoughts

Morgan Stanley’s March 02, 2026 note kept Dyne Therapeutics at Overweight while cutting the price target to $47, a mixed message of continued confidence with tempered upside. The update produced a modest 0.62% ($0.10) price move at the time the memo was reported. Investors should treat the maintained Overweight as analyst support for Dyne’s long-term prospects, but interpret the lower target as a call to refine expectations about near-term returns. Historical analyst coverage for Dyne shows shifts tied to clinical milestones and funding events, so a single maintained rating should be read alongside upcoming catalysts. Meyka AI rates DYN with a grade of B. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and we are not financial advisors. For real-time updates use our AI-powered market analysis at Meyka AI and watch for further analyst notes and company disclosures.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.